SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 20, 2020
Vir Biotechnology, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
499 Illinois Street, Suite 500
San Francisco, California
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code: (415) 906-4324
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|Common Stock, $0.0001 par value per share||VIR||Nasdaq Stock Market LLC|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 5.07|| |
Submission of Matters to a Vote of Security Holders.
On May 20, 2020, Vir Biotechnology, Inc. (the Company) held its 2020 Annual Meeting of Stockholders (the Annual Meeting). As of March 27, 2020, the record date for the Annual Meeting, 109,803,505 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.
Proposal 1. Election of Directors
The Companys stockholders elected the three persons listed below as Class I Directors, each to serve until the Companys 2023 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:
Vicki Sato, Ph.D.
Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm
The Companys stockholders ratified the selection by the Audit Committee of the Companys Board of Directors of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2020. The final voting results are as follows:
|Votes For||Votes Against||Abstentions||Broker|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Vir Biotechnology, Inc.|
|Dated: May 22, 2020||By:|
|Chief Financial Officer|